Code
01D20012
Duration
01 October 2012 → 30 September 2016
Funding
Regional and community funding: Special Research Fund
Promotor
Fellow
Research disciplines
-
Medical and health sciences
- Cardiac and vascular medicine
- Gastro-enterology and hepatology
- Laboratory medicine
- Morphological sciences
- Oncology
- Palliative care and end-of-life care
- Regenerative medicine
- Other basic sciences
- Cardiac and vascular medicine
- Gastro-enterology and hepatology
- Laboratory medicine
- Morphological sciences
- Oncology
- Palliative care and end-of-life care
- Regenerative medicine
- Other clinical sciences
- Other health sciences
- Nursing
- Other paramedical sciences
- Cardiac and vascular medicine
- Gastro-enterology and hepatology
- Laboratory medicine
- Morphological sciences
- Oncology
- Palliative care and end-of-life care
- Regenerative medicine
- Other translational sciences
- Other medical and health sciences
Keywords
ER stress
angiogenesis
hepatocellular carcinoma
chemoresistance
anti-placental growth factor
farnesylthiosalicylic acid
Project description
Hepatocellular carcinoma is third cause of cancer-related mortality. Cytostatics provide no improved survival. Chemoresistance modification is needed. Hypoxia and endoplasmic reticulum stress can cause chemoresistance. The efficacy of anti-P1GF suggests that this may be a future antineoplastic. Farnesylthiosalicylic acid is RAS competitor. HCC mouse model is used to evaluate anti-P1GF and farnesylthiosalicylic acid on hypoxia, ER stress and chemoresistance.